Faculty
Oncology Division
Alphabetical list (active faculty):   
Kian-Huat Lim

Kian-Huat Lim, MD, PhD

Associate Professor

Department of Medicine

Oncology Division

Molecular Oncology

Clinical Interests

  • Pancreatic cancer
  • Colon cancer
  • Biliary cancer
  • Neuroendocrine tumor

Research Interests

  • Inflammation
  • Innate immunity
  • Immunotherapy
  • Tumor-stroma interaction
  • KRas
  • IRAK4

Contact

  • 314-362-6157 (office)
  • 314-362-7009 (lab)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8069-0012-05
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 502 McDonnell Medical Sciences Building (lab)

Peer-reviewed Manuscripts

  • The MK2/Hsp27 Axis Is a Major Survival Mechanism for Pancreatic Ductal Adenocarcinoma Under Genotoxic Stress
    Grierson PM, Dodhiawala PB, Cheng Y, Chen TH, Khawar IA, Wei Q, Zhang D, Li L, Herndon J, Monahan JB, Ruzinova MB, Lim KH
    Sci Transl Med 2021 Dec;13(622):eabb5445
  • Phospho-Ser(784)-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor
    Wang F, Vij K, Li L, Dodhiawala P, Lim KH, Shao J
    Cancers (Basel) 2021 Oct 11;13(20):13205076
  • Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial
    Kim H, Pedersen K, Olsen JR, Mutch MG, Chin RI, Glasgow SC, Wise PE, Silviera ML, Tan BR, Wang-Gillam A, Lim KH, Suresh R, Amin M, Huang Y, Henke LE, Park H, Ciorba MA, Badiyan S, Parikh PJ, Roach MC, Hunt SR
    Clin Colorectal Cancer 2021 Sep;20(3):e185-e193
  • A Case of a Pathological Complete Response to Neoadjuvant Nivolumab Plus Ipilimumab in Periampullary Adenocarcinoma
    Pothuri V, Herndon J, Ballentine SJ, Lim KH, Fields RC
    Oncologist 2021 Sep;26(9):722-726
  • Comprehensive Characterization of 536 Patient-Derived Xenograft Models Prioritizes Candidates For Targeted Treatment
    Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, DiPersio JF, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L
    NCI PDXNet Consortium

    Nat Commun 2021 Aug 24;12(1):5086
  • Phase 1 Study Combining Alisertib With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
    Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A
    Eur J Cancer 2021 Sep;154:102-110
  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution
    Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jane-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH
    Human Tumor Atlas Network (Contributors include: Lim KH)

    Cell 2020 Apr 16;181(2):236-249
  • Stroma-Targeting Strategies in Pancreatic Cancer: Past Lessons, Challenges and Prospects
    Polani F, Grierson PM, Lim KH
    World J Gastroenterol 2021 May 14;27(18):2105-2121
  • Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion
    Chaudhry S, Fields RC, Grierson PM, Lim KH
    Cancers (Basel) 2021 Mar 13;13(6):1283
  • CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma
    Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y
    ACS Nano 2021 Jan 26;15(1):1186-1198
  • Beyond Just a Tight Fortress: Contribution of Stroma to Epithelial-Mesenchymal Transition in Pancreatic Cancer
    Bulle A, Lim KH
    Signal Transduct Target Ther 2020 Oct 30;5(1):249
  • Deciphering the Role of Innate Immune NF-KB Pathway in Pancreatic Cancer
    Khurana N, Dodhiawala PB, Bulle A, Lim KH
    Cancers (Basel) 2020 Sep 19;12(9)
  • TPL2 Enforces RAS-Induced Inflammatory Signaling and Is Activated by Point Mutations
    Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH
    J Clin Invest 2020 Sep 1;130(9):4771-4790
  • The Clonal Evolution of Metastatic Colorectal Cancer
    Dang HX, Krasnick BA, White BS, Grossman JG, Strand MS, Zhang J, Cabanski CR, Miller CA, Fulton RS, Goedegebuure SP, Fronick CC, Griffith M, Larson DE, Goetz BD, Walker JR, Hawkins WG, Strasberg SM, Linehan DC, Lim KH, Lockhart AC, Mardis ER, Wilson RK, Ley TJ, Maher CA, Fields RC
    Sci Adv 2020 Jun 10;6(24):eaay9691
  • FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial
    Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC
    JAMA Oncol 2020 Aug 1;6(8):1231-1240
  • Phase Ib/II Study Combining Tosedostat With Capecitabine in Patients With Advanced Pancreatic Adenocarcinoma
    Grierson P, Teague A, Suresh R, Lim KH, Amin M, Pedersen K, Tan B, Huffman J, Boice N, Du L, Liu J, Lockhart AC, Wang-Gillam A
    J Gastrointest Oncol 2020 Feb;11(1):61-67
  • Development of Resistance to FAK Inhibition in Pancreatic Cancer Is Linked to Stromal Depletion
    Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA, Lim KH, DeNardo DG
    Gut 2020 Jan;69(1):122-132
  • Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial
    Cercek A, Boerner T, Tan BR, Chou JF, Gonen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR
    JAMA Oncol 2019 Oct 31;6(1):60-67
  • IRAK4 Mediates Colitis-Induced Tumorigenesis and Chemoresistance in Colorectal Cancer
    Li Q, Chen Y, Zhang D, Grossman J, Li L, Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, Challen GA, Liu J, Ruzinova MB, Fields RC, Lim KH
    JCI Insight 2019 Oct 3;4(19)
  • Folate Receptor Alpha-Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention With Mirvetuximab Soravtansine in Triple-Negative Breast Cancer
    Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y
    Mol Pharm 2019 Sep 3;16(9):3996-4006
  • Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
    Kaseb AO, Sanchez NS, Sen S, Kelley RK, Tan BR, Bocobo AG, Lim K, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R
    Clin Cancer Res 2019 Oct 15;25(20):6107-6118
  • Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
    Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH
    Mol Cancer Ther 2018 Oct;17(10):2144-2155
  • Tumor-Stroma IL1beta-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
    Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH
    Cancer Res 2018 Apr 1;78(7):1700-1712
  • Distinct Clinical and Magnetic Resonance Features of Metastatic Hepatocellular Carcinoma Treated With Pembrolizumab: A Case Report of Late Response After Pseudoprogression
    Grierson P, Crites D, Ruzinova MB, Yano M, Lim KH
    Hepatol Commun 2017 Dec 19;2(2):148-151
  • Pacritinib to Inhibit JAK/STAT Signaling in Refractory Metastatic Colon and Rectal Cancer
    Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC
    J Gastrointest Oncol 2017 Dec;8(6):985-989
  • Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, DiPersio JF, Kreisel FH, Lim KH
    Biol Blood Marrow Transplant 2017 Dec;23(12):2199-2204
  • Entering the Molecular Era of Gastrointestinal Oncology: Current Updates and Challenges
    Wang-Gillam A, Lim KH
    J Gastrointest Oncol 2017 Jun;8(3):377-378
  • Molecular Landscape and Sub-Classification of Gastrointestinal Cancers: A Review of Literature
    Fakhri B, Lim KH
    J Gastrointest Oncol 2017 Jun;8(3):379-386
  • Current Biologics for Treatment of Biliary Tract Cancers
    Zhao DY, Lim KH
    J Gastrointest Oncol 2017 Jun;8(3):430-440
  • Immunotherapy in Gastrointestinal Cancers
    Grierson P, Lim KH, Amin M
    J Gastrointest Oncol 2017 Jun;8(3):474-484
  • A Clinically Feasible Multiplex Proteomic Immunoassay as a Novel Functional Diagnostic for Pancreatic Ductal Adenocarcinoma
    Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A
    Oncotarget 2017 Apr 11;8(15):24250-24261
  • Utility of a Multidisciplinary Tumor Board in the Management of Pancreatic and Upper Gastrointestinal Diseases: An Observational Study
    Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC
    HPB (Oxford) 2017 Feb;19(2):133-139
  • Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
    Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH
    Clin Cancer Res 2017 Apr 1;23(7):1748-1759
  • Targeting Tumour-Associated Macrophages With CCR2 Inhibition in Combination With FOLFIRINOX in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Finding, Non-Randomised, Phase 1b Trial
    Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC
    Lancet Oncol 2016 May;17(5):651-662
  • Nanoliposomal Irinotecan Plus Fluorouracil and Folinic Acid: A New Treatment Option in Metastatic Pancreatic Cancer
    Saif Ur Rehman S, Lim K, Wang-Gillam A
    Expert Rev Anticancer Ther 2016 May;16(5):485-492
  • Advanced Pancreatic Adenocarcinoma: A Review of Current Treatment Strategies and Developing Therapies
    Teague A, Lim KH, Wang-Gillam A
    Ther Adv Med Oncol 2015 Mar;7(2):68-84
  • Toll-Like Receptor Signaling
    Lim KH, Staudt LM
    Cold Spring Harb Perspect Biol 2013 Jan 1;5(1):a011247
  • Pathogenetic Importance and Therapeutic Implications of NF-KappaB in Lymphoid Malignancies
    Lim KH, Yang Y, Staudt LM
    Immunol Rev 2012 Mar;246(1):359-78
  • Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
    Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A
    Oncologist 2012;17(2):192-200
  • RALA and RALBP1 Regulate Mitochondrial Fission at Mitosis
    Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM
    Nat Cell Biol 2011 Aug 7;13(9):1108-15
  • Oncogenically Active MYD88 Mutations in Human Lymphoma
    Ngo VN*, Young RM*, Schmitz R*, Jhavar S*, Xiao W*, Lim KH*, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (*co-first authors)
    Nature 2011 Feb 3;470(7332):115-9
  • Sec5 and Exo84 Foster Oncogenic Ras-Mediated Tumorigenesis
    Issaq SH, Lim KH, Counter CM
    Mol Cancer Res 2010 Feb;8(2):223-31
  • Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
    Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM
    Mol Cell Biol 2010 Jan;30(2):508-23
  • The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
    Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP
    Cancer Res 2008 Sep 15;68(18):7561-9
  • Tumour Maintenance Is Mediated by ENOS
    Lim KH*, Ancrile BB*, Kashatus DF*, Counter CM (*co-first authors)
    Nature 2008 Apr 3;452(7187):646-9
  • Oncogenic Ras-Induced Secretion of IL6 Is Required for Tumorigenesis
    Ancrile B, Lim KH, Counter CM
    Genes Dev 2007 Jul 15;21(14):1714-9
  • Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells
    Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM
    Curr Biol 2006 Dec 19;16(24):2385-94
  • Use of Retrovirus Expression of Interfering RNA to Determine the Contribution of Activated K-Ras and Ras Effector Expression to Human Tumor Cell Growth
    Baines AT, Lim KH, Shields JM, Lambert JM, Counter CM, Der CJ, Cox AD
    Methods Enzymol 2006;407:556-74
  • Reduction in the Requirement of Oncogenic Ras Signaling to Activation of PI3K/AKT Pathway During Tumor Maintenance
    Lim KH, Counter CM
    Cancer Cell 2005 Nov;8(5):381-92
  • Activation of RalA Is Critical for Ras-Induced Tumorigenesis of Human Cells
    Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM
    Cancer Cell 2005 Jun;7(6):533-45
  • Leveling the Playing Field
    Lim KH, Counter CM
    Mol Cell 2004 Aug 27;15(4):491-2

Book Chapters

  • TLR 9
    Lim KH
    Cancer Therapeutic Targets. SpringerReference, 2013
  • TLR 7 and 8, Resiquimod, and 852A
    Lim KH
    Cancer Therapeutic Targets. SpringerReference, 2013
  • K-Ras
    Lim KH
    Cancer Therapeutic Targets. SpringerReference, 2013
  • Chapter 21: Other GI Malignancies
    Lim KH
    Washington Manual of Hematology Oncology Subspecialty Consult. 2nd edition, 2012
  • Chapter 15: Cancer Biology
    Lim KH
    Washington Manual of Hematology Oncology Subspecialty Consult. 2nd edition, 2012
  • Comparison of the Effects of Ras Effector Mutants and Ras Effectors
    Lim KH, Counter CM
    Proteins and Cell Regulation 2006;4:257-72